Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Breast Cancer Specialty Channel

Breast Cancer
Specialty Channel

Latest News

News
Second- or Third-Line Giredestrant Among Patients With ER-Positive, HER2-Negative Advanced Breast Cancer
04/18/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 acelERA breast cancer study, giredestrant showed a favorable trend toward benefit in investigator-assessed progression-free survival among previously treated patients with ESR1-mutated, ER-positive,...
According to results from the phase 2 acelERA breast cancer study, giredestrant showed a favorable trend toward benefit in investigator-assessed progression-free survival among previously treated patients with ESR1-mutated, ER-positive,...
According to results from the...
04/18/2024
Oncology
News
FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for Unresectable or Metastatic HER2-Positive Solid Tumors
04/08/2024

Stephanie Holland 

Stephanie Holland 
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated...
04/08/2024
Oncology
News
Addition of Palbociclib to Fulvestrant Did Not Improve Progression-Free Survival Among Pre-Treated Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer
04/04/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 PACE study, the addition of palbociclib to fulvestrant did not improve PFS among patients with HR-positive, HER2-negative metastatic breast cancer who experienced disease progression after treatment with...
According to results from the phase 2 PACE study, the addition of palbociclib to fulvestrant did not improve PFS among patients with HR-positive, HER2-negative metastatic breast cancer who experienced disease progression after treatment with...
According to results from the...
04/04/2024
Oncology
News
Ribociclib Added to Endocrine Therapy Improved Disease-Free Survival Among Patients With HR-Positive, HER2-Negative Early Breast Cancer
04/04/2024

Stephanie Holland

Stephanie Holland
According to interim results from an international phase 3 trial, ribociclib plus either letrozole or anastrozole significantly improved disease-free survival among patients with HR-positive, HER2-negative early breast cancer.
According to interim results from an international phase 3 trial, ribociclib plus either letrozole or anastrozole significantly improved disease-free survival among patients with HR-positive, HER2-negative early breast cancer.
According to interim results...
04/04/2024
Oncology
News
Benefit From Adjuvant Abemaciclib Plus Endocrine Therapy Sustained Among Patients With HR-Positive, HER2-Negative Breast Cancer
02/22/2024

Stephanie Holland 

Stephanie Holland 
Updated 5-year efficacy results from the phase 3 monarchE trial demonstrated that adjuvant abemaciclib plus endocrine therapy continued to reduce the risk of invasive and distant disease recurrence beyond completion of treatment among...
Updated 5-year efficacy results from the phase 3 monarchE trial demonstrated that adjuvant abemaciclib plus endocrine therapy continued to reduce the risk of invasive and distant disease recurrence beyond completion of treatment among...
Updated 5-year efficacy results...
02/22/2024
Oncology
News
Enobosarm Shows Promise Among Patients With AR-/ER-Positive, HER2-Negative Advanced Breast Cancer
02/14/2024

Stephanie Holland 

Stephanie Holland 
Results from a phase 2 study found that enobosarm, an oral SARM demonstrated anti-tumor activity at doses of 9 mg and 18 mg among patients with AR-positive, ER-positive, HER2-negative advanced breast cancer.
Results from a phase 2 study found that enobosarm, an oral SARM demonstrated anti-tumor activity at doses of 9 mg and 18 mg among patients with AR-positive, ER-positive, HER2-negative advanced breast cancer.
Results from a phase 2 study...
02/14/2024
Oncology
News
Fulvestrant Did Not Significantly Improve Response Rate Compared to Anastrozole in ER-Positive, HER2-Negative Early Breast Cancer
02/09/2024

Stephanie Holland 

Stephanie Holland 
Results from a phase 3 trial found fulvestrant with or without anastrozole did not significantly improve 6-month endocrine-sensitive disease rate compared to anastrozole alone among postmenopausal patients with ER-positive, HER2-negative,...
Results from a phase 3 trial found fulvestrant with or without anastrozole did not significantly improve 6-month endocrine-sensitive disease rate compared to anastrozole alone among postmenopausal patients with ER-positive, HER2-negative,...
Results from a phase 3 trial...
02/09/2024
Oncology
News
Palbociclib Plus Letrozole Did Not Significantly Improve Overall Survival Among Patients With ER-Positive, HER2-Negative Breast Cancer
02/07/2024

Stephanie Holland 

Stephanie Holland 
According to updated results from the phase 3 PALOMA-2 study, palbociclib plus letrozole did not significantly improve overall survival compared to letrozole alone among patients with ER-positive, HER2-negative, advanced breast cancer.
According to updated results from the phase 3 PALOMA-2 study, palbociclib plus letrozole did not significantly improve overall survival compared to letrozole alone among patients with ER-positive, HER2-negative, advanced breast cancer.
According to updated results...
02/07/2024
Oncology
News
First-Line Administration of Subtype-Based Therapy Demonstrated Prolonged PFS Among Patients With Previously Untreated, Metastatic/Recurrent Triple-Negative Breast Cancer
01/24/2024

Stephanie Holland 

Stephanie Holland 
Results from the ongoing phase 2 FUTURE-SUPER trial demonstrated that subtype-based therapy in the first-line setting significantly prolonged PFS among patients with previously untreated, metastatic/recurrent triple-negative breast cancer.
Results from the ongoing phase 2 FUTURE-SUPER trial demonstrated that subtype-based therapy in the first-line setting significantly prolonged PFS among patients with previously untreated, metastatic/recurrent triple-negative breast cancer.
Results from the ongoing phase 2...
01/24/2024
Oncology
News
Radiotherapy Omission Among Younger, Postmenopausal Patients With PT1N0 Unifocal Breast Cancer and Favorable Tumor Biology
01/12/2024

Stephanie Holland 

Stephanie Holland 
Long-term follow-up results from the IDEA study suggest that younger postmenopausal patients with PT1N0 unifocal invasive breast cancer harboring favorable biological features can potentially omit radiotherapy and experience high disease...
Long-term follow-up results from the IDEA study suggest that younger postmenopausal patients with PT1N0 unifocal invasive breast cancer harboring favorable biological features can potentially omit radiotherapy and experience high disease...
Long-term follow-up results from...
01/12/2024
Oncology
News
FDA Approves Adjuvant Alectinib for Patients With Resected ALK-Positive Non-Small Cell Lung Cancer
04/19/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 3 ALINA trial, the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer.
Based on results from the phase 3 ALINA trial, the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer.
Based on results from the phase...
04/19/2024
Oncology
News
IV High-Dose Methotrexate With IT Liposomal Cytarabine and R-CHOP Effective for Patients With Risk of CNS Relapse, Including DLBCL With Primary Testis Localization
04/19/2024

Amber Denham

Amber Denham
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results,...
04/19/2024
Oncology
News
Elranatamab vs Teclistamab Treatment Among Patients With Triple-Class Exposed/Refractory Multiple Myeloma
04/19/2024

Jordan Kadish 

Jordan Kadish 
According to findings from an unanchored matching-adjusted indirect comparison, elranatamab exhibited significantly better response and survival outcomes among patients with triple-class exposed/refractory multiple myeloma, compared with...
According to findings from an unanchored matching-adjusted indirect comparison, elranatamab exhibited significantly better response and survival outcomes among patients with triple-class exposed/refractory multiple myeloma, compared with...
According to findings from an...
04/19/2024
Oncology
News
Venetoclax Monotherapy Demonstrates Deep, Durable Responses Among Adult Patients With R/R CLL
04/18/2024

Amber Denham

Amber Denham
According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including BCRi-pretreated patients.
According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including BCRi-pretreated patients.
According to phase 3b results...
04/18/2024
Oncology
News
Venetoclax With Low-Dose Cytarabine Demonstrates Efficacy, Tolerability for Patients With AML at First MRD or Oligoblastic Relapse
04/18/2024

Amber Denham

Amber Denham
Venetoclax with low-dose cytarabine is well-tolerated and highly effective among patients with acute myeloid leukemia at first measurable residual disease or oligoblastic relapse, according to a phase 2 study.
Venetoclax with low-dose cytarabine is well-tolerated and highly effective among patients with acute myeloid leukemia at first measurable residual disease or oligoblastic relapse, according to a phase 2 study.
Venetoclax with low-dose...
04/18/2024
Oncology
News
Adjuvant Alectinib Significantly Improved Disease-Free Survival Among Patients With Resected ALK-Positive Non-Small Cell Lung Cancer
04/18/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 3 ALINA trial, adjuvant alectinib significantly improved disease-free survival among patients with resected ALK-positive stage IB, II, or IIIA non-small cell lung cancer.
According to results from the phase 3 ALINA trial, adjuvant alectinib significantly improved disease-free survival among patients with resected ALK-positive stage IB, II, or IIIA non-small cell lung cancer.
According to results from the...
04/18/2024
Oncology
News
Second- or Third-Line Giredestrant Among Patients With ER-Positive, HER2-Negative Advanced Breast Cancer
04/18/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 acelERA breast cancer study, giredestrant showed a favorable trend toward benefit in investigator-assessed progression-free survival among previously treated patients with ESR1-mutated, ER-positive,...
According to results from the phase 2 acelERA breast cancer study, giredestrant showed a favorable trend toward benefit in investigator-assessed progression-free survival among previously treated patients with ESR1-mutated, ER-positive,...
According to results from the...
04/18/2024
Oncology
News
Pazopanib Failed to Improve Long-Term Survival Results Among Patients With Metastatic Renal Cell Carcinoma Post-Metastasectomy at High Risk of Recurrence
04/16/2024

Stephanie Holland 

Stephanie Holland 
According to results from the ECOG-ACRIN E2810 study, pazopanib did not improve long-term disease-free survival or overall survival among patients with metastatic renal cell carcinoma with no evidence of disease after metastasectomy at high...
According to results from the ECOG-ACRIN E2810 study, pazopanib did not improve long-term disease-free survival or overall survival among patients with metastatic renal cell carcinoma with no evidence of disease after metastasectomy at high...
According to results from the...
04/16/2024
Oncology
News
Atezolizumab Plus Cabozantinib Failed to Improve Survival Among Previously Treated Patients With Metastatic Non-Small Cell Lung Cancer
04/09/2024

Stephanie Holland 

Stephanie Holland 
Results from the phase 3 CONTACT-01 trial demonstrated that atezolizumab plus cabozantinib did not improve OS or PFS compared to docetaxel among patients with metastatic NSCLC who experienced disease progression after prior treatment.
Results from the phase 3 CONTACT-01 trial demonstrated that atezolizumab plus cabozantinib did not improve OS or PFS compared to docetaxel among patients with metastatic NSCLC who experienced disease progression after prior treatment.
Results from the phase 3...
04/09/2024
Oncology
News
Potential Benefits From Neoadjuvant Chemotherapy for Patients With Locally Advanced Colon Cancer
04/09/2024

Stephanie Holland 

Stephanie Holland 
Results from the phase 3 OPTICAL study found potential benefits from neoadjuvant mFOLFOX6 or CAPOX among patients with locally advanced colon cancer.
Results from the phase 3 OPTICAL study found potential benefits from neoadjuvant mFOLFOX6 or CAPOX among patients with locally advanced colon cancer.
Results from the phase 3 OPTICAL...
04/09/2024
Oncology

Advertisement

Quizzes

Quiz
First-Line Administration of Subtype-Based Therapy for Patients With Previously Untreated, Metastatic/Recurrent Triple-Negative Breast Cancer
02/02/2024
True or False: Results from the ongoing phase 2 FUTURE-SUPER trial demonstrated that subtype-based therapy in the first-line setting significantly prolonged progression-free survival (PFS) among patients with previously untreated, metastatic...
True or False: Results from the ongoing phase 2 FUTURE-SUPER trial demonstrated that subtype-based therapy in the first-line setting significantly prolonged progression-free survival (PFS) among patients with previously untreated, metastatic...
True or False: Results from the...
02/02/2024
Oncology
Quiz
Quiz: Are All CDK4/6 Inhibitors Created Equal?
12/15/2022
How did CDK4/6 inhibitor palbociclib impact overall survival in patients with ER+/HER2- breast cancer?
How did CDK4/6 inhibitor palbociclib impact overall survival in patients with ER+/HER2- breast cancer?
How did CDK4/6 inhibitor...
12/15/2022
Oncology
Quiz
Quiz: Breast Cancer Subtypes With Differing Times to Recurrence
12/15/2022
Was the time-to-recurrence better for patients with ER-positive/HER2-negative breast cancer with the HER-2E biomarker compared to those without?
Was the time-to-recurrence better for patients with ER-positive/HER2-negative breast cancer with the HER-2E biomarker compared to those without?
Was the time-to-recurrence...
12/15/2022
Oncology
Quiz
Quiz: Brain Metastasis and Breast Cancer Subtype
12/14/2022
Is there a link between brain metastasis incidence and breast cancer subtype among patients with metastatic breast cancer?
Is there a link between brain metastasis incidence and breast cancer subtype among patients with metastatic breast cancer?
Is there a link between brain...
12/14/2022
Oncology
Quiz
Quiz: PATH Regimen for ERBB2+ Breast Cancer
12/14/2022
What was the pathological complete response rate of patients with ERBB2-positive breast cancer treated with the PATH regimen?
What was the pathological complete response rate of patients with ERBB2-positive breast cancer treated with the PATH regimen?
What was the pathological...
12/14/2022
Oncology
Quiz
Quiz: Effect of Tomaxafin on Hemorrhage Risk
12/14/2022
Did treatment with tamoxifen plus a direct oral anticoagulant for breast cancer increase patient hemorrhage risk vs an aromatase inhibitor plus direct oral anticoagulant?
Did treatment with tamoxifen plus a direct oral anticoagulant for breast cancer increase patient hemorrhage risk vs an aromatase inhibitor plus direct oral anticoagulant?
Did treatment with tamoxifen...
12/14/2022
Oncology
Quiz
Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Advanced Triple-Negative Breast Cancer
11/04/2022
Did results of the the KEYNOTE-355 trial find that pembrolizumab plus chemotherapy improved overall survival vs chemotherapy alone in patients with advanced triple-negative breast cancer?
Did results of the the KEYNOTE-355 trial find that pembrolizumab plus chemotherapy improved overall survival vs chemotherapy alone in patients with advanced triple-negative breast cancer?
Did results of the the...
11/04/2022
Oncology
Quiz
Quiz: [18F]FES-PET or Biopsy to Determine ER Status of Metastatic Breast Cancer?
08/30/2022
How diagnostically accurate is 16a-[18F]fluoro-17b-estradiol positron emission tomography to assess ER status of metastatic breast cancer vs biopsy of a metastasis?
How diagnostically accurate is 16a-[18F]fluoro-17b-estradiol positron emission tomography to assess ER status of metastatic breast cancer vs biopsy of a metastasis?
How diagnostically accurate is...
08/30/2022
Oncology
Quiz
Quiz: Breast Cancer PFS With Elacestrant vs Standard Endocrine Monotherapy
08/30/2022
Which patients, if any, experienced improved progression-free survival when treated with elacestrant compared to standard of care endocrine monotherapy?
Which patients, if any, experienced improved progression-free survival when treated with elacestrant compared to standard of care endocrine monotherapy?
Which patients, if any,...
08/30/2022
Oncology
Quiz
Quiz: Does Trastuzumab Deruxtecan Show Greater Efficacy than Standard of Care in HER2-Positive BC?
04/26/2022
True or false: Trastuzumab deruxtecan was associated with significantly lower risk of disease progression over current standard of care for HER2-positive metastatic breast cancer.
True or false: Trastuzumab deruxtecan was associated with significantly lower risk of disease progression over current standard of care for HER2-positive metastatic breast cancer.
True or false: Trastuzumab...
04/26/2022
Oncology
Quiz
Induction Therapy With High-Dose Chemo, Autologous HSCT in Patients With PCNSL
04/11/2024
04/11/2024
Oncology
Quiz
Amivantamab Plus Chemotherapy for Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer
04/04/2024
According to results from the phase 3 PAPILLON trial, what percentage of patients remained on amivantamab plus chemotherapy at a follow-up of 18-months?
According to results from the phase 3 PAPILLON trial, what percentage of patients remained on amivantamab plus chemotherapy at a follow-up of 18-months?
According to results from the...
04/04/2024
Oncology
Quiz
Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer
04/04/2024
True or False: Results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial demonstrated that tisotumab vedotin in the second-/third-line setting significantly improved survival and response outcomes compared to chemotherapy for patients with...
True or False: Results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial demonstrated that tisotumab vedotin in the second-/third-line setting significantly improved survival and response outcomes compared to chemotherapy for patients with...
True or False: Results from the...
04/04/2024
Oncology
Quiz
Efficacy of Imatinib vs Dasatinib Prophylaxis Among Patients With Philadelphia-Positive ALL Following ASCT
04/02/2024
04/02/2024
Oncology
Quiz
Chemo-Free Mosunetuzumab Monotherapy for 3 L+ Follicular Lymphoma
03/27/2024
True or False: According to findings from a real-world data comparison, mosunetuzumab monotherapy demonstrated promising outcomes as a chemotherapy-free option among patients with follicular lymphoma treated with 3 or more lines of systemic...
True or False: According to findings from a real-world data comparison, mosunetuzumab monotherapy demonstrated promising outcomes as a chemotherapy-free option among patients with follicular lymphoma treated with 3 or more lines of systemic...
True or False: According to...
03/27/2024
Oncology
Quiz
Combination of Pembrolizumab and Vorinostat for PD-1 Blockade Refractory cHL
03/25/2024
What was the key finding from a dose-expansion study assessing a combination of pembrolizumab plus vorinostat among patients with R/R classical Hodgkin lymphoma, particularly among those refractory to PD-1 blockade?
What was the key finding from a dose-expansion study assessing a combination of pembrolizumab plus vorinostat among patients with R/R classical Hodgkin lymphoma, particularly among those refractory to PD-1 blockade?
What was the key finding from a...
03/25/2024
Oncology
Quiz
Belzutifan vs Everolimus for Quality of Life of Patients With Advanced Clear Cell Renal Cell Carcinoma
03/21/2024
Did belzutifan improve the time to deterioration among patients with advanced clear cell renal cell carcinoma when compared with everolimus?
Did belzutifan improve the time to deterioration among patients with advanced clear cell renal cell carcinoma when compared with everolimus?
Did belzutifan improve the time...
03/21/2024
Oncology
Quiz
FDA Approves Osimertinib Plus Chemotherapy For EGFR-Mutated Advanced NSCLC
03/21/2024
Based on results from the phase 3 FLAURA 2 trial the US FDA has approved osimertinib plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon...
Based on results from the phase 3 FLAURA 2 trial the US FDA has approved osimertinib plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon...
Based on results from the phase...
03/21/2024
Oncology
Quiz
Capivasertib Plus Fulvestrant Improved PFS in Advanced Breast Cancer
03/11/2024
Study results indicated that the addition of capivasertib to fulvestrant improved PFS from 3.6 months to ____ months.
Study results indicated that the addition of capivasertib to fulvestrant improved PFS from 3.6 months to ____ months.
Study results indicated that the...
03/11/2024
Oncology
Quiz
Treating Acute Myeloid Leukemia With Aspacytarabine
03/05/2024
True or False: Aspacytarabine demonstrated efficacy and safety among patients with acute myeloid leukemia who were young and fit for intensive chemotherapy, according to a phase 2b trial.
True or False: Aspacytarabine demonstrated efficacy and safety among patients with acute myeloid leukemia who were young and fit for intensive chemotherapy, according to a phase 2b trial.
True or False: Aspacytarabine...
03/05/2024
Oncology

Advertisement

Advertisement

Advertisement

Hear From the Experts:

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement